"Virtual Pharma" Pharmaceutical Developability Network

banner
Major drug developers are examining current R&D practices and, in some cases, considering a radical overhaul of their R&D models.  A new model of drug development is emerging, which focuses on more efficient utilisation of existing resources across the academic, biotechnology, contract research organisation and pharma sectors.  Particularly important in the this full integrated Pharmaceutical Network (FIPNet) model is the formation of closer alliances between drug developers and contract research organisations in order to reduce overhead costs, increase efficiency, and bolster output.

Consideration of these changes in the model of pharmaceutical development is critical for achieving successful translation of Australia’s discoveries in the pharmaceutical area.  However, Australia lacks ‘big pharma’ research capability and as a result, lacks infrastructure and critical mass in several areas fundamental to the successful implementation of the FIPNet model.  Notable among these are translational chemistry capability and access to drug screening programs that provide deeper insight into potential development pathways. 

To address the current challenges to drug development in Australia, TIA has created the “Virtual Pharma” Pharmaceutical Developability Network (PDN). 

The key elements of the PDN are:
  • An expert panel with experienced translational health experts to guide research
  • A translational chemistry facility
  • Primary and secondary drug screening capability
  • Preclinical capacity with a focus on specific gaps in relation to toxicology
  • Pharmacometric capability across the drug development sector
  • The PDN expert panel provides researchers with advice on translational health that mimics the pharma capability in FIPNet models.   It provides a coordinating focus for FIPNet style development programs and an aggregation of existing drug development expertise and capability.  The PDN guides researchers on drug development with a greater emphasis on translational outcomes and will also provide a vehicle for closer alliances between researchers and other sectors in the FIPNet. 
THD funding will be provided to the key areas of:
  1. Primary Drug Screening
  2. Secondary Drug Screening
  3. Electrophysiology
  4. Translational Chemistry
  5. Preclinical Capacity
  6. Immunotoxicology
  7. Pharmacometrics
For researchers interested in using the PDN to facilitate their translational research, please contact TIA.